GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSX) » Definitions » Altman Z-Score
中文

Boston Scientific (Boston Scientific) Altman Z-Score : 4.82 (As of Apr. 25, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Boston Scientific Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 4.6 is strong.

Boston Scientific has a Altman Z-Score of 4.82, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Boston Scientific's Altman Z-Score or its related term are showing as below:

BSX' s Altman Z-Score Range Over the Past 10 Years
Min: 0.71   Med: 2.47   Max: 4.6
Current: 4.6

During the past 13 years, Boston Scientific's highest Altman Z-Score was 4.60. The lowest was 0.71. And the median was 2.47.


Boston Scientific Altman Z-Score Historical Data

The historical data trend for Boston Scientific's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Altman Z-Score Chart

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.63 2.34 2.86 3.27 3.96

Boston Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 3.52 3.75 3.80 3.96

Competitive Comparison of Boston Scientific's Altman Z-Score

For the Medical Devices subindustry, Boston Scientific's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Altman Z-Score falls into.



Boston Scientific Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Boston Scientific's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.045+1.4*0.0233+3.3*0.0641+0.6*6.8672+1.0*0.4053
=4.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $35,136 Mil.
Total Current Assets was $6,514 Mil.
Total Current Liabilities was $4,933 Mil.
Retained Earnings was $819 Mil.
Pre-Tax Income was 505 + 610 + 426 + 444 = $1,985 Mil.
Interest Expense was -65 + -66 + -70 + -65 = $-266 Mil.
Revenue was 3725 + 3527 + 3599 + 3389 = $14,240 Mil.
Market Cap (Today) was $107,170 Mil.
Total Liabilities was $15,606 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(6514 - 4933)/35136
=0.045

X2=Retained Earnings/Total Assets
=819/35136
=0.0233

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(1985 - -266)/35136
=0.0641

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=107170.073/15606
=6.8672

X5=Revenue/Total Assets
=14240/35136
=0.4053

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Boston Scientific has a Altman Z-Score of 4.82 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Boston Scientific  (NYSE:BSX) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Boston Scientific Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (Boston Scientific) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Executives
Joseph Michael Fitzgerald officer: SVP & President, Endovascular C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Jeffrey B. Mirviss officer: SVP&Pres, Periph Intervent C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Wendy Carruthers officer: SVP, Human Resources C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Arthur C Butcher officer: SVP&Pres, Endoscopy C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Michael F Mahoney officer: President BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Vance R Brown officer: SVP, GC and Corp. Secretary C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Susan E Morano director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jessica L Mega director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Thepaut Eric Francis Yves officer: SVP & Pres, Europe C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
John Bradley Sorenson officer: SVP, Glob Ops & Qual C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jonathan Monson officer: VP, Corp Controller and CAO C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Daniel J. Brennan officer: EVP and CFO BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Nelda J Connors director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Scott Olson officer: SVP & Pres, Rhythm Management C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752